OpenURL Connection Search

Select item for more details and to access through your institution.

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Published in:
Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231156392
By:
- Emmett, Louise;
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Counter, William;
- Ayers, Maria;
- Sharma, Shikha;
- Agrawal, Shikha;
- Poole, Aron;
- Hovey, Elizabeth;
- Pranavan, Ganes;
- Gedye, Craig;
- Mallesara, Girish;
- Guminski, Alex;
- Lee, Adrian;
- Stockler, Martin R.;
- Hickey, Adam;
- Eu, Peter;
- Joshua, Anthony M.;
- Crumbaker, Megan;
- Nguyen, Andrew
Publication type:
Article
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
Published in:
Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267014
By:
- Swiha, Mina;
- Papa, Nathan;
- Sabahi, Zahra;
- Ayati, Narjess;
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Li, Sherrington;
- Agrawal, Shikha;
- Ayers, Maria;
- Hickey, Adam;
- Sharma, Shikha;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
Published in:
Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 904, doi. 10.2967/jnumed.123.267014
By:
- Swiha, Mina;
- Papa, Nathan;
- Sabahi, Zahra;
- Ayati, Narjess;
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Li, Sherrington;
- Agrawal, Shikha;
- Ayers, Maria;
- Hickey, Adam;
- Sharma, Shikha;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy.
Published in:
Journal of Nuclear Medicine, 2023, v. 64, n. 9, p. 1412, doi. 10.2967/jnumed.123.265759
By:
- Kumar, Shejil;
- Crumbaker, Megan;
- Harvey, Christopher;
- Pathmanandavel, Sarennya;
- John, Nikieth;
- Swiha, Mina M.;
- McDonald, Michelle M.;
- Clifton-Bligh, Roderick;
- 7–, Adrian Lee;
- Bastick, Patricia;
- Counter, William;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 221, doi. 10.2967/jnumed.122.264398
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Bao Ho;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Hickey, Adam;
- Eu, Peter;
- Stockler, Martin;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.
Published in:
Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 410, doi. 10.2967/jnumed.122.264677
By:
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Counter, William;
- Bao Ho;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Poole, Aron;
- Hickey, Adam;
- Agrawal, Shikha;
- Perkins, Gary;
- Kallinen, Annukka;
- Eslick, Enid;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2023, v. 64, n. 1, p. 69, doi. 10.2967/jnumed.122.264104
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Nguyen, Andrew;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Eu, Peter;
- Martin, Andrew J.;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264677
By:
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Counter, William;
- Bao Ho;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Poole, Aron;
- Hickey, Adam;
- Agrawal, Shikha;
- Perkins, Gary;
- Kallinen, Annukka;
- Eslick, Enid;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264398
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Ho, Bao;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Hickey, Adam;
- Eu, Peter;
- Stockler, Martin;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264104
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Nguyen, Andrew;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Eu, Peter;
- Martin, Andrew J.;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177 Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264677
By:
- John, Nikeith;
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Counter, William;
- Bao Ho;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Poole, Aron;
- Hickey, Adam;
- Agrawal, Shikha;
- Perkins, Gary;
- Kallinen, Annukka;
- Eslick, Enid;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264398
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Ho, Bao;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Hickey, Adam;
- Eu, Peter;
- Stockler, Martin;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Nguyen, Andrew;
- Emmett, Louise
Publication type:
Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264104
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Nguyen, Andrew;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Eu, Peter;
- Martin, Andrew J.;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.264104
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Nguyen, Andrew;
- Yam, Andrew O.;
- Wilson, Peter;
- Niman, Remy;
- Ayers, Maria;
- Sharma, Shikha;
- Eu, Peter;
- Martin, Andrew J.;
- Stockler, Martin R.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262552
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Yam, Andrew O.;
- Nguyen, Andrew;
- Rofe, Christopher;
- Hovey, Elizabeth;
- Gedye, Craig;
- Kwan, Edmond M.;
- Hauser, Christine;
- Azad, Arun A.;
- Eu, Peter;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262552
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Yam, Andrew O.;
- Nguyen, Andrew;
- Rofe, Christopher;
- Hovey, Elizabeth;
- Gedye, Craig;
- Kwan, Edmond M.;
- Hauser, Christine;
- Azad, Arun A.;
- Eu, Peter;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262552
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Yam, Andrew O.;
- Nguyen, Andrew;
- Rofe, Christopher;
- Hovey, Elizabeth;
- Gedye, Craig;
- Kwan, Edmond M.;
- Hauser, Christine;
- Azad, Arun A.;
- Eu, Peter;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262552
By:
- Pathmanandavel, Sarennya;
- Crumbaker, Megan;
- Yam, Andrew O.;
- Nguyen, Andrew;
- Rofe, Christopher;
- Hovey, Elizabeth;
- Gedye, Craig;
- Kwan, Edmond M.;
- Hauser, Christine;
- Azad, Arun A.;
- Eu, Peter;
- Martin, Andrew J.;
- Joshua, Anthony M.;
- Emmett, Louise
Publication type:
Article
Expression of growth differentiation factor 6 in the human developing fetal spine retreats from vertebral ossifying regions and is restricted to cartilaginous tissues.
Published in:
Journal of Orthopaedic Research, 2016, v. 34, n. 2, p. 279, doi. 10.1002/jor.22983
By:
- Wei, Aiqun;
- Shen, Bojiang;
- Williams, Lisa A.;
- Bhargav, Divya;
- Gulati, Twishi;
- Fang, Zhimin;
- Pathmanandavel, Sarennya;
- Diwan, Ashish D.
Publication type:
Article

Found: 19

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).

Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub> and Patient Outcomes.

Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.

The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy.

Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T Therapy.

The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).

<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.

Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).

<sup>177</sup> Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.

Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).

The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).

<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.

<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.

<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.

<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.

Expression of growth differentiation factor 6 in the human developing fetal spine retreats from vertebral ossifying regions and is restricted to cartilaginous tissues.